Peter Martin
Chief of the Lymphoma Program · Weill Cornell Medicine
Credentials: · ·
History
PresentLymphoma Program Division · Weill Cornell Medicine
- Present
- 2001
University of Alberta Faculty of Medicine
Research
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
New England Journal of Medicine · 2013 · 1,377 citations
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
New England Journal of Medicine · 2014 · 893 citations
Blood · 2015 · 355 citations
93 papers
- BK
44 papers
42 papers
36 papers
32 papers
- MC
31 papers
29 papers
26 papers
Clinical trials
- 2023–2026
Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma
Principal investigator · Withdrawn
Weill Medical College of Cornell University
- 2015–2021
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Principal investigator · Completed · Phase 1
Weill Medical College of Cornell University
- 2012–2014
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
Principal investigator · Terminated · Phase 2
Weill Medical College of Cornell University
- 2010–2012
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Principal investigator · Completed · Phase 2
S*BIO